Search Results

You are looking at 1 - 10 of 586 items for :

  • "Transplant" x
Clear All
Full access

Marcy Neuburg

Starzl TE . De novo malignant tumors in organ transplant recipients . Transplant Proc 1971 ; 3 : 773 – 778 . 4. Sheil AG Disney AP Mathew TH Amiss N . De novo malignancy emerges as a major cause of morbidity and late failure in renal

Full access

Leona Holmberg and David G. Maloney

complete remission, the disease may become life-threatening. For many patients, the current standard of care involves salvage chemotherapy and autologous hematopoietic stem cell transplantation (ASCT). Successful outcome depends on chemosensitivity at the

Full access

Justin A. Chen, Naseem Esteghamat, Edward J. Kim, Gabriel Garcia, Jun Gong, Marwan G. Fakih, Richard J. Bold and May T. Cho

, such as MLH1, MSH2, MSH6, and PMS2. 1 , 2 However, most large, prospective clinical trials investigating checkpoint blockade in MSI metastatic colorectal cancer (mCRC) have excluded patients who received a liver transplant. 1 , 3 The safety and

Full access

Potjana Jitawatanarat, Arpita Desai, Pradeep Sharda, Hong Liu, Maureen Ross, Francisco J. Hernandez-llizaliturri, Philip L. McCarthy and George L. Chen

’ institution for further treatment. Cytogenetic evaluation revealed mutation of p53 , del(13q), and del(11q). Because of the high-risk features of his disease, an allogeneic hematopoietic cell transplant (alloHCT) was planned and a donor search initiated. In

Full access

Howard A. Chang, Saro H. Armenian and Thanh H. Dellinger

viral etiology of most lower genital tract cancers, women who are immunocompromised and thus unable to eliminate HPV or suppress its activity may be at a higher risk of developing these cancers. 7 , 8 For example, solid organ transplant recipients who

Full access

Philip L. McCarthy

combination regimens, have made a major impact on time to progression (TTP), PFS, and OS. Attaining and maintaining response have been important goals in the management of MM after autologous hematopoietic stem cell transplant (AHSCT). 1 , 14 Researchers have

Full access

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger and James O. Armitage

to the recommendation of allogeneic stem cell transplantation (allo-SCT) whenever possible, 6 but its prognostic significance and the optimal treatment of Ph + -AML are not clear. With the current treatment options, the outcome is dismal (with a

Full access

Boglarka Gyurkocza and Frederick R. Appelbaum

years or older, treated on several SWOG, ECOG, and MD Anderson Cancer Center protocols between 1976 and 2004, reported a 5-year overall survival rate of 7%. 7 The application of allogeneic hematopoietic cell transplantation (HCT) to patients with AML in

Full access

Maxim Norkin and John R. Wingard

Because of prolonged neutropenia and severe immunosuppression, patients with hematologic malignancies (HMs) and hematopoietic stem cell transplant (HSCT) recipients are at high risk for invasive fungal infections (IFIs), which are associated with

Full access

Jean F. Botha and Alan N. Langnas

transplantation in cancer therapy . Ann Surg 1985 ; 202 : 401 – 407 . 2. Ringe B Wittekind C Bechstein WO . The role of liver transplantation in the treatment of liver cancer . Cancer Chemother Pharmacol 1989 ; 23 ( suppl ): S104 – S109